文献速递呼吸衰竭与机械通气儿科与产科急症重症综合管理与镇静镇痛

气管内表面活性物质治疗婴儿危及生命的毛细支气管炎(BESS):一项随机、盲法、假对照2期试验

Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial.
PubMed 文献 · Lancet Respir Med · 2026-03-21
一句话结论对需要IMV的早期危重毛细支气管炎婴儿,气管内给予猪肺表面活性物质(200 mg/kg首剂,后100 mg/kg每12小时,最多3剂)虽安全,但未缩短IMV时长,作者认为该剂量和给药方式下不应为此适应症使用。

BESS为多中心、盲法、随机、假对照、平行组、2期优效性试验,在英格兰、苏格兰和北爱尔兰15个儿科ICU纳入胎龄校正后小于26周、因毛细支气管炎需有创机械通气的早产和足月婴儿,1:1随机接受最多3剂气管内猪肺表面活性物质(Curosurf;首剂200 mg/kg,后100 mg/kg,间隔12小时)或假干预。主要终点为从随机化至最终成功拔管的有创机械通气时长,意向性治疗分析。共232例随机(表面活性物质组115例,假干预组117例),表面活性物质组中位IMV 64.9小时(IQR 43.2–92.1)vs 假干预组62.0小时(IQR 39.3–95.1),几何均数比1.02(95%CI 0.84–1.24;t检验P=0.86)。无临床显著安全问题和死亡。作者认为该剂量和给药方式下不应为此适应症使用。

要点

  • 在需IMV的早期危重毛细支气管炎婴儿中,气管内猪肺表面活性物质组中位IMV时长为64.9小时(IQR 43.2–92.1),假干预组为62.0小时(IQR 39.3–95.1),几何均数比1.02(95%CI 0.84–1.24;P=0.86)。
  • 表面活性物质组与假干预组之间IMV时长无显著差异,作者据此认为该剂量(首剂200 mg/kg,后100 mg/kg每12小时)和给药方式下不应为此适应症使用。
  • 试验未观察到与气管内猪肺表面活性物质相关的临床显著安全问题,无死亡。
  • 该试验为2期优效性设计,纳入胎龄校正后小于26周、因毛细支气管炎需IMV的早产和足月婴儿,按随机化前IMV时长(<24小时和≥24小时)及中心分层。

适用人群与场景

  • 胎龄校正后小于26周的早产和足月婴儿,因毛细支气管炎入住医院并需要有创机械通气(IMV)。
  • 试验在英格兰、苏格兰和北爱尔兰的15个儿科重症监护病房进行。
  • 随机化按随机化前IMV时长(<24小时和≥24小时)及中心分层。

处置流程与药物剂量

  • 气管内给予猪肺表面活性物质(Curosurf):首剂200 mg/kg,随后100 mg/kg,间隔12小时,最多3剂。
  • 对照组接受假干预。

研究设计与关键结果

  • BESS为多中心、盲法、随机、假对照、平行组、2期优效性试验,在15个儿科ICU进行,2018年12月18日至2024年3月31日共评估1009例,随机232例(表面活性物质组115例,假干预组117例);130例(56%)为男性,102例(44%)为女性;3例退出研究,无失访。
  • 主要终点:从随机化至最终成功拔管的有创机械通气时长,表面活性物质组中位64.9小时(IQR 43.2–92.1)vs 假干预组62.0小时(IQR 39.3–95.1),几何均数比1.02(95%CI 0.84–1.24;t检验P=0.86)。
  • 安全性:未观察到与气管内猪肺表面活性物质相关的临床显著安全问题,无死亡。

证据类型、等级与局限

  • 证据类型:多中心、盲法、随机、假对照、平行组、2期优效性试验(BESS)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对早期危重毛细支气管炎婴儿,气管内猪肺表面活性物质虽安全,但未缩短IMV时长,该剂量和给药方式下不应为此适应症使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Bronchiolitis is a common viral respiratory disease of infants, with severity ranging from mild symptoms, such as coryza and feeding difficulties, to fulminant respiratory failure. Endotracheal administration of exogenous surfactant has been shown in small studies to improve gas exchange in critically ill infants with bronchiolitis. We aimed to investigate the safety and efficacy of endotracheal poractant alfa for treating critical bronchiolitis compared with a sham procedure.

METHODS: BESS was a multicentre, blinded, randomised, sham-controlled, parallel-group, phase 2, superiority trial with exploratory mechanism evaluation studies. The trial was done in 15 paediatric intensive care units in the devolved National Health Service (NHS) of England, Scotland, and Northern Ireland. Preterm and term-born infants younger than 26 weeks of gestationally corrected age admitted to hospitals with bronchiolitis requiring invasive mechanical ventilation (IMV) were randomly assigned (1:1) to receive up to three doses of endotracheal poractant alfa (Curosurf) or sham intervention, allocated through web-based randomisation. Randomisation was stratified by duration of IMV before randomisation (<24 h and ≥24 h) and by site. The infants and their families, clinical care staff, Liverpool Clinical Trial Centre staff, and members of the site research teams were masked to treatment allocations. Endotracheal poractant alfa was given initially at 200 mg/kg, followed by 100 mg/kg at 12 h intervals. The primary endpoint was the duration of IMV from randomisation to final successful extubation. All infants who were successfully extubated were included in the intention-to-treat analysis. Safety outcomes were analysed in infants who had received at least one trial intervention. This trial was registered prospectively with ISRCTN (ISRCTN11746266) and EudraCT (2018-001169-18), and is completed.

FINDINGS: The trial was completed after six recruitment seasons. Between Dec 18, 2018, to March 31, 2024, 1009 infants were assessed for eligibility, 232 of whom were randomly assigned to receive either endotracheal poractant alfa (n=115) or a sham intervention (n=117). 130 (56%) of 232 infants were male and 102 (44%) were female. Three infants were withdrawn from the study. None were lost to follow-up. The median duration of IMV was 64·9 h (IQR 43·2-92·1) in the endotracheal poractant alfa group and 62·0 h (39·3-95·1) in the sham intervention group. The geometric mean ratio was 1·02 (95% CI 0·84-1·24; t-test p=0·86). No clinically significant safety issues were associated with endotracheal poractant alfa and there were no deaths.

INTERPRETATION: Poractant alfa, administered endotracheally to infants with early critical bronchiolitis, although safe, did not reduce the duration of IMV compared with the sham intervention. Therefore, our findings suggest that it should not be used for this indication at this dose and administration method.

FUNDING: UK National Institute for Health and Care Research, UK Research and Innovation Medical Research Council, Chief Scientist Office Scotland, Health and Social Care Research and Development Division Northern Ireland, and Chiesi Farmaceutici, Italy.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Semple MG, Donohue C, Price L, et al. Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial. Lancet Respir Med. 2026. PMID: 41875912. doi:10.1016/S2213-2600(26)00008-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。